Goldman Sachs Group Inc Dia Medica Therapeutics Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 68,948 shares of DMAC stock, worth $417,824. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,948Holding current value
$417,824% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DMAC
# of Institutions
45Shares Held
4.57MCall Options Held
8.2KPut Options Held
200-
Vanguard Group Inc Valley Forge, PA1.24MShares$7.53 Million0.0% of portfolio
-
First Manhattan CO New York, NY839KShares$5.08 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX483KShares$2.92 Million3.74% of portfolio
-
Bleichroeder LP New York, NY382KShares$2.32 Million0.54% of portfolio
-
Geode Capital Management, LLC Boston, MA307KShares$1.86 Million0.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $160M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...